Compare GRFS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | DNTH |
|---|---|---|
| Founded | 1940 | 2015 |
| Country | Spain | United States |
| Employees | 25247 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.6B |
| IPO Year | N/A | 2018 |
| Metric | GRFS | DNTH |
|---|---|---|
| Price | $7.99 | $86.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $10.15 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 589.6K | 422.6K |
| Earning Date | 07-28-2022 | 05-06-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $4.49 | N/A |
| Revenue Next Year | $6.42 | $29.48 |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.39 | $16.77 |
| 52 Week High | $11.14 | $96.50 |
| Indicator | GRFS | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 49.95 |
| Support Level | $7.87 | $82.00 |
| Resistance Level | $9.78 | $90.23 |
| Average True Range (ATR) | 0.21 | 4.58 |
| MACD | 0.02 | -0.20 |
| Stochastic Oscillator | 50.26 | 52.27 |
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.